# Setmelanotide (Imcivree)

> MC4R agonist for rare genetic obesity disorders.

Source: https://peptides.cafe/peptide/setmelanotide
Category: Melanocortin Agonist · Metabolic
Tag: FDA-Approved · Rare Disease

## Mechanism
Cyclic 8-amino-acid melanocortin-4 receptor (MC4R) agonist that restores signaling in the leptin–melanocortin pathway, addressing hyperphagia and obesity in specific genetic deficiencies (POMC, PCSK1, LEPR, Bardet–Biedl syndrome).

## Research areas
- POMC/LEPR/PCSK1 deficiency obesity
- Bardet–Biedl syndrome

## Common research protocols
- Daily: 1–3 mg SC daily, titrated; pediatric dosing available.

## Study summaries
- "Setmelanotide phase 3 trials" — Lancet Diabetes & Endocrinology (2020): Significant weight loss and hunger reduction in genetic obesity syndromes.

## Considerations
- FDA-approved.
- Hyperpigmentation, injection-site reactions common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.